NO20035474D0 - Prodrugs av GABA-analoger, sammensetninger og anvendelse derav - Google Patents
Prodrugs av GABA-analoger, sammensetninger og anvendelse deravInfo
- Publication number
- NO20035474D0 NO20035474D0 NO20035474A NO20035474A NO20035474D0 NO 20035474 D0 NO20035474 D0 NO 20035474D0 NO 20035474 A NO20035474 A NO 20035474A NO 20035474 A NO20035474 A NO 20035474A NO 20035474 D0 NO20035474 D0 NO 20035474D0
- Authority
- NO
- Norway
- Prior art keywords
- prodrugs
- gaba analogs
- compositions
- methods
- gaba
- Prior art date
Links
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 title abstract 6
- 239000000651 prodrug Substances 0.000 title abstract 6
- 229940002612 prodrug Drugs 0.000 title abstract 6
- 239000000203 mixture Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
- C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
- C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
- C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/06—Seven-membered rings having the hetero atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/32—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D317/34—Oxygen atoms
- C07D317/40—Vinylene carbonate; Substituted vinylene carbonates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20083956A NO20083956L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
NO20083958A NO20083958L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29752101P | 2001-06-11 | 2001-06-11 | |
US29851401P | 2001-06-14 | 2001-06-14 | |
US36609002P | 2002-03-19 | 2002-03-19 | |
PCT/US2002/018689 WO2002100347A2 (en) | 2001-06-11 | 2002-06-11 | Prodrugs of gaba analogs, compositions and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20035474D0 true NO20035474D0 (no) | 2003-12-09 |
NO333756B1 NO333756B1 (no) | 2013-09-09 |
Family
ID=27404495
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035473A NO20035473D0 (no) | 2001-06-11 | 2003-12-09 | Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet |
NO20035474A NO333756B1 (no) | 2001-06-11 | 2003-12-09 | Forbindelser, anvendelse derav samt farmasoytiske sammensetninger |
NO20083958A NO20083958L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
NO20083956A NO20083956L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20035473A NO20035473D0 (no) | 2001-06-11 | 2003-12-09 | Oralt administrerte doseringsformer av GABA-analogprodrugs som har reduserttoksisitet |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083958A NO20083958L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
NO20083956A NO20083956L (no) | 2001-06-11 | 2008-09-16 | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav |
Country Status (21)
Country | Link |
---|---|
US (2) | US6833140B2 (no) |
EP (4) | EP1902714B1 (no) |
JP (4) | JP4216713B2 (no) |
KR (5) | KR20040016882A (no) |
CN (1) | CN1533270A (no) |
AT (2) | ATE380029T1 (no) |
AU (4) | AU2002345664C1 (no) |
CA (2) | CA2449673A1 (no) |
CY (1) | CY1107894T1 (no) |
DE (1) | DE60223923T3 (no) |
DK (1) | DK1404324T4 (no) |
ES (2) | ES2296956T5 (no) |
HK (2) | HK1087628A1 (no) |
HU (2) | HUP0400167A3 (no) |
IL (5) | IL159299A0 (no) |
MX (2) | MXPA03011566A (no) |
NO (4) | NO20035473D0 (no) |
NZ (1) | NZ567711A (no) |
PT (1) | PT1404324E (no) |
WO (2) | WO2002100392A1 (no) |
ZA (1) | ZA200309679B (no) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1077692E (pt) * | 1998-05-15 | 2004-12-31 | Warner Lambert Co | Preparacoes farmaceuticas estabilizadas de derivados do acido aminobutirico e processos para a sua preparacao |
EP1343805A4 (en) * | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
WO2002044324A2 (en) | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
AU2002230398A1 (en) | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
EP1343515A4 (en) * | 2000-10-06 | 2005-08-03 | Xenoport Inc | COMPOUNDS FOR PROLONGED RELEASE OF ORAL DRUGS |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US7232924B2 (en) * | 2001-06-11 | 2007-06-19 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs |
AU2002345638A1 (en) * | 2001-06-11 | 2002-12-23 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
US7186855B2 (en) * | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
CA2449673A1 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
AU2002357506A1 (en) * | 2001-12-25 | 2003-07-15 | Takeda Chemical Industries, Ltd. | Acid-containing preparations |
WO2003077902A1 (en) | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
AU2003297909A1 (en) * | 2002-12-11 | 2004-06-30 | Xenoport, Inc. | Orally administered dosage forms of fused gaba analog prodrugs having reduced toxicity |
AU2003286300A1 (en) * | 2002-12-13 | 2004-07-09 | Warner-Lambert Company Llc | Pregabalin and derivates thereof for the treatment of fibromyalgia and other related disorders |
CA2509605C (en) | 2002-12-13 | 2010-10-05 | Warner-Lambert Company Llc | Alpha-2-delta ligand to treat lower urinary tract symptoms |
CA2451267A1 (en) | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
US8641987B2 (en) | 2003-01-24 | 2014-02-04 | Applied Biosystems, Llc | Sample chamber array and method for processing a biological sample |
MXPA05010515A (es) | 2003-03-31 | 2006-03-10 | Xenoport Inc | Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba. |
US7169812B2 (en) | 2003-07-01 | 2007-01-30 | Medtronic, Inc. | Process for producing injectable gabapentin compositions |
WO2005010011A2 (en) * | 2003-07-15 | 2005-02-03 | Xenoport, Inc. | Methods of synthesis of acyloxyalkyl compounds |
EP2354120A1 (en) * | 2003-08-20 | 2011-08-10 | XenoPort, Inc. | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
KR20110097942A (ko) | 2003-08-20 | 2011-08-31 | 제노포트 인코포레이티드 | 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법 |
SG145759A1 (en) * | 2003-08-20 | 2008-09-29 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
AU2004272111A1 (en) * | 2003-09-11 | 2005-03-24 | Xenoport, Inc. | Treating and/or preventing urinary incontinence using prodrugs of GABA analogs |
ATE449633T1 (de) | 2003-09-12 | 2009-12-15 | Pfizer | Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern |
RU2377234C2 (ru) * | 2003-09-17 | 2009-12-27 | Ксенопорт, Инк. | Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк |
JP5107576B2 (ja) * | 2003-09-17 | 2012-12-26 | ゼノポート,インコーポレイティド | Gaba類似体のプロドラッグを使用する不穏下肢症候群の治療または予防 |
SI1677767T1 (sl) * | 2003-10-14 | 2011-11-30 | Xenoport Inc | Kristalinična oblika analoga gama-aminomaslene kisline |
WO2005041976A2 (en) * | 2003-10-23 | 2005-05-12 | Medtronic, Inc. | Injectable gabapentin compositions |
EP2371815A1 (en) * | 2003-12-30 | 2011-10-05 | XenoPort, Inc. | Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
CN1902175B (zh) * | 2003-12-30 | 2012-08-22 | 什诺波特有限公司 | 酰氧基烃基氨基甲酸酯前药及其中间体的合成 |
WO2005087709A1 (en) * | 2004-03-17 | 2005-09-22 | Hikal Limited | 4-t-butylgabapentin and its synthesis |
CN1946391A (zh) * | 2004-04-20 | 2007-04-11 | 辉瑞产品公司 | 包含α-2-δ配体的组合 |
US7494985B2 (en) | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
US7566738B2 (en) | 2004-11-03 | 2009-07-28 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
BRPI0517227B8 (pt) | 2004-11-04 | 2021-05-25 | Xenoport Inc | comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido |
US20060182805A1 (en) * | 2005-02-15 | 2006-08-17 | Jazz Pharmaceuticals | Dosage form and method for sustained release of substituted pyrazine compound |
CN101253148B (zh) * | 2005-06-20 | 2013-01-02 | 克塞诺波特公司 | 凝血酸的酰氧基烷基氨基甲酸酯前药,合成和使用的方法 |
US20070049627A1 (en) * | 2005-08-23 | 2007-03-01 | Tran Pierre V | Treating vulvodynia using prodrugs of GABA analogs |
US20070049626A1 (en) * | 2005-08-26 | 2007-03-01 | Tran Pierre V | Treating premature ejaculation using gabapentin and pregabalin prodrugs |
KR20080041722A (ko) * | 2005-08-31 | 2008-05-13 | 와이어쓰 | 글리실사이클린의 9-아미노카르보닐 치환된 유도체 |
US7727978B2 (en) * | 2006-08-24 | 2010-06-01 | Bristol-Myers Squibb Company | Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors |
US7585996B2 (en) | 2006-09-15 | 2009-09-08 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
US7879906B2 (en) | 2006-11-24 | 2011-02-01 | Anchen Laboratories, Inc. | GABA analogs, compositions and methods for manufacturing thereof |
AU2007325686A1 (en) * | 2006-11-30 | 2008-06-05 | Cenerx Biopharma, Inc. | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders |
US20080161393A1 (en) * | 2006-12-08 | 2008-07-03 | Barrett Ronald W | Use of prodrugs of GABA analogs for treating disease |
WO2008077599A1 (en) | 2006-12-22 | 2008-07-03 | Recordati Ireland Limited | COMBINATION THERAPY OF LOWER URINARY TRACT DISORDERS WITH α2δ LIGANDS AND NSAIDS |
US20090041806A1 (en) * | 2007-06-15 | 2009-02-12 | Xenoport, Inc. | Use of prodrugs of gaba analogs, antispasticity agents, and prodrugs of gaba b receptor agonists for treating spasticity |
KR101307686B1 (ko) | 2007-07-20 | 2013-09-12 | 아미리스 인코퍼레이티드 | 테트라메틸시클로헥산을 포함하는 연료 조성물 |
US20090118365A1 (en) * | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
WO2009094577A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
JP5563483B2 (ja) * | 2008-01-25 | 2014-07-30 | ゼノポート,インコーポレイティド | アシロキシアルキルカルバメートプロドラッグの合成に使用されるアシロキシアルキルチオカーボネートの鏡像異性的な分解 |
WO2009094563A2 (en) | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
WO2010017504A1 (en) | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
WO2010017498A1 (en) * | 2008-08-07 | 2010-02-11 | Xenoport, Inc. | Methods of synthesizing n-hydroxysuccinimidyl carbonates |
WO2010063002A2 (en) | 2008-11-26 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
JP5500164B2 (ja) | 2009-03-02 | 2014-05-21 | アステラス製薬株式会社 | 固形製剤の包装体 |
CA2753860A1 (en) * | 2009-03-06 | 2010-09-10 | Xenoport, Inc. | Oral dosage forms having a high loading of a gabapentin prodrug |
WO2011101245A1 (en) | 2010-02-18 | 2011-08-25 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neuropathic pain |
BR112013000164B1 (pt) | 2010-07-30 | 2021-11-23 | Toray Industries, Inc | Agente terapêutico ou agente profilático |
WO2013163889A1 (en) * | 2012-05-03 | 2013-11-07 | Dsm Ip Assets B.V. | New intermediate compound for preparing vitamin b6 |
EP2961730A2 (en) | 2013-02-26 | 2016-01-06 | XenoPort, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
ES2894903T3 (es) | 2013-11-05 | 2022-02-16 | Astrazeneca Ab | Profármacos antagonistas de NMDA |
US20190247331A1 (en) | 2018-02-15 | 2019-08-15 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
US10213393B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság | Composition and method for treating neurological disease |
US10213394B1 (en) | 2018-02-15 | 2019-02-26 | Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság | Composition and method for treating neurological disease |
WO2020074160A1 (en) * | 2018-10-10 | 2020-04-16 | Curovir Ab | Condensed pyrimidine or pyridazine derivatives as antiviral agents |
CN114306234A (zh) * | 2021-12-23 | 2022-04-12 | 江苏百奥信康医药科技有限公司 | 一种含有加巴喷丁复合物的tpgs胶束口服液及其制备方法 |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002A (en) * | 1841-03-12 | Tor and planter for plowing | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US2996431A (en) * | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
US3402240A (en) * | 1957-06-25 | 1968-09-17 | Pfizer & Co C | Medicinal tablet and process of making same |
US3139383A (en) * | 1961-06-26 | 1964-06-30 | Norton Co | Encapsulated time release pellets and method for encapsulating the same |
GB1364672A (en) * | 1971-06-09 | 1974-08-29 | Beecham Group Ltd | Penicillins |
US3962414A (en) * | 1972-04-27 | 1976-06-08 | Alza Corporation | Structured bioerodible drug delivery device |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3811444A (en) * | 1972-12-27 | 1974-05-21 | Alza Corp | Bioerodible ocular device |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
US3992414A (en) * | 1973-12-20 | 1976-11-16 | Lever Brothers Company | Process for the preparation of selectively halogenated ketals |
US3992518A (en) * | 1974-10-24 | 1976-11-16 | G. D. Searle & Co. | Method for making a microsealed delivery device |
GB1478759A (en) * | 1974-11-18 | 1977-07-06 | Alza Corp | Process for forming outlet passageways in pills using a laser |
US4087544A (en) | 1974-12-21 | 1978-05-02 | Warner-Lambert Company | Treatment of cranial dysfunctions using novel cyclic amino acids |
DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4036064A (en) * | 1975-09-11 | 1977-07-19 | Gilford Instrument Laboratories, Inc. | Pipette device |
US4093571A (en) * | 1976-01-14 | 1978-06-06 | Celanese Corporation | Process for making porous metal containing powder coating compositions |
US4063064A (en) * | 1976-02-23 | 1977-12-13 | Coherent Radiation | Apparatus for tracking moving workpiece by a laser beam |
US4079038A (en) * | 1976-03-05 | 1978-03-14 | Alza Corporation | Poly(carbonates) |
US4066747A (en) * | 1976-04-08 | 1978-01-03 | Alza Corporation | Polymeric orthoesters housing beneficial drug for controlled release therefrom |
US4070347A (en) * | 1976-08-16 | 1978-01-24 | Alza Corporation | Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality |
US4189571A (en) * | 1978-02-07 | 1980-02-19 | Fisons Limited | Esters of cromoglycates |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
FR2476087A1 (fr) * | 1980-02-18 | 1981-08-21 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments |
JPS57193489A (en) * | 1981-05-21 | 1982-11-27 | Fujisawa Pharmaceut Co Ltd | Syn-isomer of 7-substituted-3-cephem-4-carboxylic acid ester and its preparation |
US4434153A (en) * | 1982-03-22 | 1984-02-28 | Alza Corporation | Drug delivery system comprising a reservoir containing a plurality of tiny pills |
US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
US4721613A (en) * | 1982-12-13 | 1988-01-26 | Alza Corporation | Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use |
US4760057A (en) * | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
DE3475065D1 (en) * | 1983-06-23 | 1988-12-15 | Merck & Co Inc | (acyloxyalkoxy) carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs, their preparation and pharmaceutical compositions containing said derivatives |
US4611056A (en) * | 1983-10-05 | 1986-09-09 | Merck Frosst Canada, Inc. | Benzo[A]phenothiazines and hydro-derivatives |
EP0138481B1 (en) * | 1983-10-05 | 1991-06-26 | Merck Frosst Canada Inc. | Leukotriene biosynthesis inhibitors |
DE3479397D1 (en) * | 1983-10-05 | 1989-09-21 | Merck Frosst Canada Inc | Benzoûa¨phenothiazines and hydro-derivatives and pharmaceutical compositions containing them |
US4916230A (en) * | 1984-07-02 | 1990-04-10 | Merck & Co., Inc. | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
US5051448A (en) * | 1984-07-24 | 1991-09-24 | The Mclean Hospital Corporation | GABA esters and GABA analog esters |
US4820523A (en) * | 1986-04-15 | 1989-04-11 | Warner-Lambert Company | Pharmaceutical composition |
US4752470A (en) * | 1986-11-24 | 1988-06-21 | Mehta Atul M | Controlled release indomethacin |
IL87710A (en) * | 1987-09-18 | 1992-06-21 | Ciba Geigy Ag | Covered floating retard form for controlled release in gastric juice |
US4816263A (en) * | 1987-10-02 | 1989-03-28 | Alza Corporation | Dosage form for treating cardiovascular diseases comprising isradipine |
US4853229A (en) * | 1987-10-26 | 1989-08-01 | Alza Corporation | Method for adminstering tiny pills |
DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
PH26730A (en) * | 1988-12-30 | 1992-09-28 | Ciba Geigy Ag | Coated adhesive tablets |
DE3928183A1 (de) | 1989-08-25 | 1991-02-28 | Goedecke Ag | Lactamfreie cyclische aminosaeuren |
US5084169A (en) * | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5084479A (en) * | 1990-01-02 | 1992-01-28 | Warner-Lambert Company | Novel methods for treating neurodegenerative diseases |
GB9001405D0 (en) * | 1990-01-22 | 1990-03-21 | Leo Pharm Prod Ltd | New intermediates,their production and use |
EP0458751A1 (en) * | 1990-05-25 | 1991-11-27 | Warner-Lambert Company | Delivery system for cyclic amino acids with improved taste, texture and compressibility |
JPH04103574A (ja) * | 1990-08-22 | 1992-04-06 | Kumiai Chem Ind Co Ltd | ピリミジン誘導体及び除草剤 |
US5827819A (en) * | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
AU9137091A (en) | 1990-11-27 | 1992-06-25 | Northwestern University | Gaba and l-glutamic acid analogs for antiseizure treatment |
US6197819B1 (en) * | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
TW209174B (no) * | 1991-04-19 | 1993-07-11 | Takeda Pharm Industry Co Ltd | |
US5698155A (en) | 1991-05-31 | 1997-12-16 | Gs Technologies, Inc. | Method for the manufacture of pharmaceutical cellulose capsules |
GB9204918D0 (en) | 1992-03-06 | 1992-04-22 | Nycomed As | Chemical compounds |
RU2140901C1 (ru) | 1992-05-20 | 1999-11-10 | Нортвестерн Юниверсити | АНАЛОГИ γ-АМИНОМАСЛЯНОЙ КИСЛОТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ |
WO1993025197A1 (en) | 1992-06-12 | 1993-12-23 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
WO1995010519A1 (en) | 1993-10-14 | 1995-04-20 | Abbott Laboratories | Quinolizinone type compounds |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
US5466811A (en) * | 1994-07-18 | 1995-11-14 | Merck & Co., Inc. | Dioxolenylmethyl carbamates pro moieties for amine drugs |
US5684018A (en) | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
US5672584A (en) * | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
WO1996038435A1 (en) | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
NZ326669A (en) | 1996-02-07 | 2001-05-25 | Warner Lambert Co | Thiopyran or pyran derivatives useful as pharmaceutical agents |
SK282848B6 (sk) | 1996-03-14 | 2002-12-03 | Warner-Lambert Company | Premostené cyklické aminokyseliny, farmaceutická kompozícia obsahujúca tieto aminokyseliny |
JP2000506861A (ja) * | 1996-03-14 | 2000-06-06 | ワーナー―ランバート・コンパニー | 医薬としての新規な置換環状アミノ酸 |
DK0934061T6 (en) | 1996-07-24 | 2015-01-26 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
CN1073103C (zh) | 1996-07-30 | 2001-10-17 | 阿瑞斯药物公司 | 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 |
US5962473A (en) | 1996-08-16 | 1999-10-05 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of common cold or allergic rhinitis with serotonin 5-HT1F |
US6375987B1 (en) * | 1996-10-01 | 2002-04-23 | Gattefossé, S.A. | Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix |
US6153650A (en) | 1996-10-23 | 2000-11-28 | Warner-Lambert Company | Substituted gamma aminobutyric acids as pharmaceutical agents |
WO1999000127A1 (en) | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
WO1999008670A1 (en) | 1997-08-20 | 1999-02-25 | Guglietta, Antonio | Gaba analogs to prevent and treat gastrointestinal damage |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
US6740682B2 (en) * | 1997-08-29 | 2004-05-25 | Tularik Limited | Meta-benzamidine derivatives as serine protease inhibitors |
HUP0004310A3 (en) | 1997-10-27 | 2001-11-28 | Warner Lambert Co | Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents |
CU23028A3 (es) | 1997-12-16 | 2005-02-23 | Warner Lambert Co | Aminas novedosas como agentes farmaceuticos. |
EP1047678B1 (en) | 1997-12-16 | 2004-09-08 | Warner-Lambert Company LLC | 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
AU759392B2 (en) | 1997-12-16 | 2003-04-10 | Warner-Lambert Company | 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders |
CA2309354A1 (en) | 1998-01-23 | 1999-07-29 | Leslie Magnus-Miller | Gabapentin and its derivatives for the treatment of muscular and skeletal pain |
BR9910697A (pt) | 1998-05-26 | 2001-01-30 | Warner Lambert Co | Compostos aminoácidos comprimidos estruturalmente tendo afinidade à subunidade alfa2delta de um canal de cálcio |
FR2779651B1 (fr) * | 1998-06-16 | 2001-04-20 | Gattefosse Ets Sa | Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero |
US6171615B1 (en) * | 1998-07-06 | 2001-01-09 | Gattefoss{acute over (e)} | Sustained release theophylline formulations, excipient systems and methods of production |
NZ510145A (en) | 1998-09-14 | 2003-02-28 | Warner Lambert Co | Branched alkyl pyrrolidine-3-carboxylic acids useful in protective action against cardiazole cramp and cerebral conditions such as epilepsy, hypokinesia and cranial traumas |
DK1121114T3 (da) * | 1998-10-16 | 2007-04-10 | Warner Lambert Co | Anvendelse af GABA-analoger til fremstilling af et medikament til behandling af mani og bipolære lidelser |
CO5210925A1 (es) * | 1998-11-17 | 2002-10-30 | Novartis Ag | Derivados de diamino nitroguanidina tetrasustituidos |
AU1602100A (en) | 1998-11-25 | 2000-06-13 | Warner-Lambert Company | Improved gamma amino butyric acid analogs |
EP1031350A1 (en) * | 1999-02-23 | 2000-08-30 | Warner-Lambert Company | Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain |
AU3313900A (en) * | 1999-05-27 | 2000-12-18 | Pfizer Products Inc. | Mutual prodrugs of amlodipine and atorvastatin |
CA2689997A1 (en) * | 1999-06-10 | 2000-12-21 | Warner-Lambert Company Llc | Mono- and disubstituted 3-propyl gamma-aminobutyric acids |
HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
ATE308510T1 (de) * | 1999-12-08 | 2005-11-15 | Warner Lambert Co | Inhibitore der verzweigte-aminosäure-abhängigen aminotransferase und deren verwendung in der behandlung der zuckerkranke retinopathie |
JP2004501067A (ja) * | 2000-01-28 | 2004-01-15 | ローム アンド ハース カンパニー | 高められた特性をもつ医薬 |
WO2001062242A1 (en) * | 2000-02-24 | 2001-08-30 | Biocryst Pharmaceuticals, Inc. | Prodrugs of substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
CZ302807B6 (cs) * | 2000-05-25 | 2011-11-23 | F. Hoffmann-La Roche Ag | Substituovaný 1-aminoalkyllaktam, zpusob jeho prípravy a použití pro výrobu léciva a farmaceutická kompozice s jeho obsahem |
GB2362646A (en) * | 2000-05-26 | 2001-11-28 | Warner Lambert Co | Cyclic amino acid derivatives useful as pharmaceutical agents |
JP3909842B2 (ja) | 2000-06-26 | 2007-04-25 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 睡眠障害のためのガバペンチン類似物 |
WO2002004458A1 (en) * | 2000-07-07 | 2002-01-17 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
EP1301516B1 (en) * | 2000-07-07 | 2006-03-22 | Novo Nordisk A/S | Modulators of protein tyrosine phosphatases (ptpases) |
GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
GB2365425A (en) * | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
DZ3415A1 (fr) * | 2000-08-31 | 2002-03-07 | Chiron Corp | Guanidinobenzamides comme mc4-r agonistes. |
WO2002044324A2 (en) * | 2000-10-06 | 2002-06-06 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
EP1343805A4 (en) * | 2000-10-06 | 2005-07-20 | Xenoport Inc | COMPOUNDS DERIVED FROM GALLENIC ACIDS FOR THE PROVISION OF CONTINUING SYSTEMIC CONCENTRATIONS OF MEDICINAL PRODUCTS AFTER ORAL ADMINISTRATION |
AU2002230398A1 (en) * | 2000-10-06 | 2002-04-29 | Xenoport, Inc. | Bile-acid conjugates for providing sustained systemic concentrations of drugs |
AU2002213393B2 (en) * | 2000-10-20 | 2007-02-15 | Biocryst Pharmaceuticals, Inc. | Biaryl compounds as serine protease inhibitors |
US6683112B2 (en) * | 2000-10-24 | 2004-01-27 | Andrx Corporation | Gabapentin prodrugs and formulations |
GB2368579A (en) * | 2000-10-31 | 2002-05-08 | Parke Davis & Co Ltd | Azole pharmaceutical agents |
AU2002239257A1 (en) * | 2000-11-17 | 2002-06-03 | Xenoport, Inc. | Amino acid conjugates providing for sustained systemic concentrations of gaba analogues |
WO2002062766A2 (en) * | 2001-02-07 | 2002-08-15 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
EP1401423A4 (en) * | 2001-05-29 | 2006-08-16 | Depomed Dev Ltd | METHOD FOR THE TREATMENT OF GASTROÖSOPHAGEAL REFLUX DISEASE AND NURSING ACID BREAKDOWN |
US6818787B2 (en) * | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
CA2449673A1 (en) * | 2001-06-11 | 2002-12-19 | Xenoport, Inc. | Orally administered dosage forms of gaba analog prodrugs having reduced toxicity |
GB0115517D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
WO2003011255A1 (en) * | 2001-07-04 | 2003-02-13 | Sun Pharmaceutical Industries Limited | Gastric retention controlled drug delivery system |
EP2301550A1 (en) * | 2001-07-13 | 2011-03-30 | Paratek Pharmaceuticals, Inc. | Tetracycline compounds having target therapeutic activities |
US7053076B2 (en) * | 2001-08-29 | 2006-05-30 | Xenoport, Inc. | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs |
TWI312285B (en) * | 2001-10-25 | 2009-07-21 | Depomed Inc | Methods of treatment using a gastric retained gabapentin dosage |
US6723340B2 (en) * | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
US20030158254A1 (en) * | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
WO2003077902A1 (en) * | 2002-02-19 | 2003-09-25 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
US20050032135A1 (en) * | 2003-07-03 | 2005-02-10 | Xenoport, Inc. | Monocarboxylate transporters expressed in cancer cells |
WO2005121787A2 (en) * | 2004-06-04 | 2005-12-22 | Xenoport, Inc. | Lat1 transporters expressed in cancer cells |
TW200616604A (en) * | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
-
2002
- 2002-06-11 CA CA002449673A patent/CA2449673A1/en not_active Abandoned
- 2002-06-11 AU AU2002345664A patent/AU2002345664C1/en not_active Ceased
- 2002-06-11 IL IL15929902A patent/IL159299A0/xx unknown
- 2002-06-11 EP EP07020763A patent/EP1902714B1/en not_active Expired - Lifetime
- 2002-06-11 EP EP02744314A patent/EP1404324B2/en not_active Expired - Lifetime
- 2002-06-11 KR KR10-2003-7016204A patent/KR20040016882A/ko not_active Application Discontinuation
- 2002-06-11 NZ NZ567711A patent/NZ567711A/en unknown
- 2002-06-11 PT PT02744314T patent/PT1404324E/pt unknown
- 2002-06-11 HU HU0400167A patent/HUP0400167A3/hu not_active Application Discontinuation
- 2002-06-11 WO PCT/US2002/018701 patent/WO2002100392A1/en active Application Filing
- 2002-06-11 AU AU2002310409A patent/AU2002310409C1/en not_active Ceased
- 2002-06-11 EP EP02737485A patent/EP1404310A4/en not_active Withdrawn
- 2002-06-11 MX MXPA03011566A patent/MXPA03011566A/es active IP Right Grant
- 2002-06-11 US US10/170,127 patent/US6833140B2/en not_active Expired - Lifetime
- 2002-06-11 IL IL15930002A patent/IL159300A0/xx unknown
- 2002-06-11 AT AT02744314T patent/ATE380029T1/de active
- 2002-06-11 HU HU0400183A patent/HUP0400183A2/hu unknown
- 2002-06-11 CA CA002449729A patent/CA2449729C/en not_active Expired - Lifetime
- 2002-06-11 AT AT07020763T patent/ATE540678T1/de active
- 2002-06-11 KR KR1020097022012A patent/KR20090121404A/ko not_active Application Discontinuation
- 2002-06-11 KR KR1020037016230A patent/KR100926921B1/ko active IP Right Grant
- 2002-06-11 DK DK02744314.2T patent/DK1404324T4/da active
- 2002-06-11 KR KR1020097001793A patent/KR100958552B1/ko active IP Right Grant
- 2002-06-11 JP JP2003516067A patent/JP4216713B2/ja not_active Expired - Fee Related
- 2002-06-11 DE DE60223923T patent/DE60223923T3/de not_active Expired - Lifetime
- 2002-06-11 WO PCT/US2002/018689 patent/WO2002100347A2/en active Application Filing
- 2002-06-11 MX MXPA03011565A patent/MXPA03011565A/es active IP Right Grant
- 2002-06-11 ES ES02744314T patent/ES2296956T5/es not_active Expired - Lifetime
- 2002-06-11 CN CNA028145836A patent/CN1533270A/zh active Pending
- 2002-06-11 KR KR1020077024007A patent/KR20070108282A/ko not_active Application Discontinuation
- 2002-06-11 ES ES07020763T patent/ES2380287T3/es not_active Expired - Lifetime
- 2002-06-11 EP EP09003173A patent/EP2085087A1/en not_active Withdrawn
- 2002-06-11 JP JP2003503214A patent/JP2004534057A/ja active Pending
-
2003
- 2003-12-09 NO NO20035473A patent/NO20035473D0/no not_active Application Discontinuation
- 2003-12-09 NO NO20035474A patent/NO333756B1/no not_active IP Right Cessation
- 2003-12-10 IL IL159300A patent/IL159300A/en active IP Right Grant
- 2003-12-12 ZA ZA2003/09679A patent/ZA200309679B/en unknown
-
2004
- 2004-04-21 US US10/829,896 patent/US20040198820A1/en not_active Abandoned
-
2006
- 2006-07-14 HK HK06107881.1A patent/HK1087628A1/xx not_active IP Right Cessation
-
2007
- 2007-07-19 AU AU2007203364A patent/AU2007203364B2/en not_active Ceased
-
2008
- 2008-02-25 CY CY20081100218T patent/CY1107894T1/el unknown
- 2008-06-30 JP JP2008171250A patent/JP2009051822A/ja not_active Withdrawn
- 2008-06-30 JP JP2008171589A patent/JP5001227B2/ja not_active Expired - Lifetime
- 2008-09-16 NO NO20083958A patent/NO20083958L/no not_active Application Discontinuation
- 2008-09-16 NO NO20083956A patent/NO20083956L/no not_active Application Discontinuation
- 2008-09-17 AU AU2008221505A patent/AU2008221505C1/en not_active Ceased
-
2009
- 2009-03-26 IL IL197843A patent/IL197843A/en active IP Right Grant
- 2009-08-10 HK HK09107301.0A patent/HK1129103A1/xx not_active IP Right Cessation
-
2011
- 2011-06-19 IL IL213649A patent/IL213649A0/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
NO20034056D0 (no) | Proliferative sykdommer | |
ATE455092T1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
HK1092467A1 (en) | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n- | |
IS6922A (is) | Heterófjölhringjaefnasambönd og notkun þeirra semmetabótrópísk mótlyf gegn glútamat viðtökum | |
ATE492279T1 (de) | Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen | |
ATE361288T1 (de) | N-(3,-dimethylindolin-6-yl)ä2-ä(4- | |
EA200801711A1 (ru) | Пролекарства возбуждающих аминокислот | |
WO2005046603A3 (en) | Pyridine compounds | |
NO20043085L (no) | Fremgangsmater og sammensetninger for behandling av forstyrrelser i sentralnervesystemet | |
BR0316723A (pt) | Derivados de anilinopirazol úteis para o tratamento de diabetes | |
ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
NO20044530L (no) | Fremgangsmate for behandling av kognitive forstyrrelser | |
CY1110368T1 (el) | Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη | |
ATE473737T1 (de) | Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung | |
EA201001895A1 (ru) | Пролекарства возбуждающих аминокислот |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |